

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/791,367	0/791,367 03/02/2004		Kristian Pietras	NEX90/C	9750
25871	7590	11/29/2005		EXAMINER	
SWANSOI 1745 SHEA		ATSCHUN L.L.C.	VIVLEMORE, TRACY ANN		
SUITE 330	CENTEN	DIGVE	ART UNIT	PAPER NUMBER	
HIGHLANI	OS RANC	H, CO 80129	1635		

DATE MAILED: 11/29/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Appli	cation No.	Applicant(s)						
Office Action Summary			1,367	PIETRAS ET AL.						
			iner	Art Unit						
		Tracy	Vivlemore	1635						
Period fo	The MAILING DATE of this commur or Reply	ication appears or	the cover sheet	with the correspondence ac	Idress					
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE M nsions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comr o period for reply is specified above, the maximum state or to reply within the set or extended period for reply reply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	MAILING DATE OF s of 37 CFR 1.136(a). In r nunication. atutory period will apply a v will, by statute, cause the	THIS COMMUN to event, however, may a and will expire SIX (6) MC application to become	IICATION. A reply be timely filed DNTHS from the mailing date of this c ABANDONED (35 U.S.C. § 133).						
Status										
1)	Responsive to communication(s) file	ed on								
2a) □	•	2b)⊠ This action	is non-final.							
3)										
,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Disposit	on of Claims	·								
4)⊠	4)⊠ Claim(s) <u>1-14</u> is/are pending in the application.									
	4a) Of the above claim(s) is/are withdrawn from consideration.									
5)	Claim(s) is/are allowed.									
6)[Claim(s) is/are rejected.									
7)										
8)⊠	8) Claim(s) 1-14 are subject to restriction and/or election requirement.									
Applicati	on Papers									
9)	The specification is objected to by th	e Examiner.								
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.										
Priority ι	ınder 35 U.S.C. § 119									
	12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
	1. Certified copies of the priority documents have been received.									
	 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage 									
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).									
* 5	* See the attached detailed Office action for a list of the certified copies not received.									
			ormiou ocpioo no	. rosonou.						
Attachmen	t(s)									
1) Notic	e of References Cited (PTO-892)			Summary (PTO-413)						
	e of Draftsperson's Patent Drawing Review (F nation Disclosure Statement(s) (PTO-1449 or			o(s)/Mail Date Informal Patent Application (PTC	D-152)					
	r No(s)/Mail Date	,	6) Other:							

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-10, drawn to a method for treating tumors or increasing the uptake of cytotoxic agents into a tumor, classifiable in class 514, subclass 44.
- II. Claims 11-14, drawn to a therapeutic composition comprising a PDGF aptamer and a cytotoxic agent, classifiable in class 536, subclass 24.5.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process could be performed with a materially different product. For example the uptake of cytotoxic agents into a tumor could be increased by conjugating the cytotoxic agent to an antibody.

Furthermore, examining invention I together with invention II would impose a serious search burden. In the instant case, prior art searches of methods of treating tumors or increasing the uptake of a cytotoxic agent into a tumor are not coextensive with prior art searches of compositions of aptamers and cytotoxic agents. Search of each of these inventions would require different key word searches of each compound

Application/Control Number: 10/791,367

Art Unit: 1635

and of each distinctive step of the method using divergent patent and non-patent literature databases. The different searches would then require subsequent in-depth analysis of the unrelated prior art literature, placing a serious burden on the Office in terms of both search and examination. As such, it would be burdensome to perform examination of inventions I and II together.

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See

Art Unit: 1635

"Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tracy Vivlemore whose telephone number is 571-272-2914. The examiner can normally be reached on Mon-Fri 8:45-5:15.

Page 5

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-272-0811. The central FAX Number is 571-273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

> Tracy Vivlemore Examiner Art Unit 1635

TV

November 15, 2005